KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Capital Expenditures (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Capital Expenditures data on record, last reported at -$799.3 million in Q4 2025.

  • For Q4 2025, Capital Expenditures fell 3125.2% year-over-year to -$799.3 million; the TTM value through Dec 2025 reached $58.8 million, changed N/A, while the annual FY2025 figure was $58.8 million, N/A changed from the prior year.
  • Capital Expenditures reached -$799.3 million in Q4 2025 per JAZZ's latest filing, down from $831.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $831.2 million in Q3 2025 and bottomed at -$799.3 million in Q4 2025.
  • Average Capital Expenditures over 5 years is $7.0 million, with a median of $7.8 million recorded in 2021.
  • The widest YoY moves for Capital Expenditures: up 3253.93% in 2025, down 3125.2% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $10.0 million in 2021, then dropped by 5.91% to $9.4 million in 2022, then increased by 7.72% to $10.1 million in 2023, then crashed by 345.33% to -$24.8 million in 2024, then crashed by 3125.2% to -$799.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were -$799.3 million in Q4 2025, $831.2 million in Q3 2025, and $13.0 million in Q2 2025.